Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 25, 2018
-
Mar 29, 2018ALIS previously designated as an orphan drug, breakthrough therapy and Qualified Infectious Disease Product (QIDP)
-
Feb 23, 2018On track to file NDA before the end of March and anticipate a priority review
-
Feb 20, 2018
-
Feb 15, 2018
-
Jan 26, 2018
-
Jan 3, 2018Interim results from INS-312 show that 28% of patients who previously received 6 months of guideline based therapy (GBT) alone achieved culture conversion following addition of ALIS to therapy, consistent with data from the INS-212 study
-
Nov 8, 2017
-
Nov 2, 2017During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS (amikacin liposome inhalation suspension) in patients with NTM lung disease caused by MAC, a rare, progressive, destructive lung infection
-
Oct 25, 2017
-
Sep 11, 2017
-
Sep 5, 2017Study met primary endpoint of culture conversion (p < 0.0001)
-
Aug 3, 2017On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month
-
Jul 27, 2017
-
May 15, 2017Paolo Tombesi named as Chief Financial Officer
-
May 3, 2017Advancing Toward Top-Line Results from CONVERT Study in 2H 2017
-
Apr 26, 2017
-
Feb 23, 2017On Track to Report Top-Line Results from CONVERT Study in 2H 2017
-
Feb 16, 2017
-
Feb 14, 2017
-
Nov 3, 2016Enrollment objective achieved in phase 3 CONVERT study
-
Oct 27, 2016
-
Oct 18, 2016Data in American Journal of Respiratory and Critical Care Medicine demonstrate ARIKAYCE's potential to achieve early and sustained negative sputum cultures
-
Aug 31, 2016
-
Jun 8, 2016
Your Privacy Choices